Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment

被引:30
作者
Chirgwin, John M. [1 ]
Guise, Theresa A. [1 ]
机构
[1] Univ Virginia, Dept Med, Div Endocrinol, Aurbach Lab, Charlottesville, VA 22908 USA
关键词
bone metastases; osteoblastic metastases; osteolytic metastases; transforming growth factor beta; endothelin-1; Wnt signaling; bisphosphonates; hypoxia; GROWTH-FACTOR-BETA; BREAST-CANCER METASTASIS; PROSTATE-CANCER; CELLS; MODEL; INHIBITION; MECHANISMS; STRATEGIES; RESORPTION; PATHWAYS;
D O I
10.1002/jcb.21556
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurable and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-P. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenviroment and not the tumor cells themselves. J. Cell. Biochem. 102: 1333-1342, 2007. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:1333 / 1342
页数:10
相关论文
共 53 条
[1]
Barnes GL, 2003, CANCER RES, V63, P2631
[2]
Inhibition of transforming growth factor-β signaling in human cancer:: Targeting a tumor suppressor network as a therapeutic strategy [J].
Biswas, Swati ;
Criswell, Tracy L. ;
Wang, Shizhen Emily ;
Arteaga, Carlos L. .
CLINICAL CANCER RESEARCH, 2006, 12 (14) :4142-4146
[3]
Wnt signaling and osteoblastogenesis [J].
Bodine, Peter V. N. ;
Komm, Barry S. .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2006, 7 (1-2) :33-39
[4]
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases [J].
Boucharaba, Ahmed ;
Serre, Claire-Marie ;
Guglielmi, Julien ;
Bordet, Jean-Claude ;
Clezardin, Philippe ;
Peyruchaud, Olivier .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (25) :9643-9648
[5]
Src inhibitors in metastatic bone disease [J].
Boyce, Brendan F. ;
Xing, Lianping ;
Yao, Zhengiang ;
Yamashita, Teruhito ;
Shakespeare, William C. ;
Wang, Yihan ;
Metcalf, Chester A., III ;
Sundaramoorthi, Raji ;
Dalgarno, David C. ;
Luliucci, John D. ;
Sawyer, Tomi K. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6291S-6295S
[6]
Clinical lessons from the calcium-sensing receptor [J].
Brown, Edward M. .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (02) :122-133
[7]
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo [J].
Buijs, Jeroen T. ;
Rentsch, Cyrill A. ;
van der Horst, Geertje ;
van Civerveld, Petra G. M. ;
Wetterwald, Antoinette ;
Schwaninger, Ruth ;
Henriquez, Niek V. ;
ten Dijke, Peter ;
Borovecki, Fran ;
Markwalder, Regula ;
Thalmann, George N. ;
Papapoulos, Socrates E. ;
Pelger, Rob C. M. ;
Vukicevic, Slobodan ;
Cecchini, Marco G. ;
Lowik, Clemens W. G. M. ;
van der Pluijm, Gabri .
AMERICAN JOURNAL OF PATHOLOGY, 2007, 171 (03) :1047-1057
[8]
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists [J].
Carducci, Michael A. ;
Jimeno, Antonio .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6296S-6300S
[9]
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation [J].
Clines, Gregory A. ;
Mohammad, Khalid S. ;
Bao, Yongde ;
Stephens, Owen W. ;
Suva, Larry J. ;
Shaughnessy, John D., Jr. ;
Fox, Jay W. ;
Chirgwin, John M. ;
Guise, Theresa A. .
MOLECULAR ENDOCRINOLOGY, 2007, 21 (02) :486-498
[10]
The new bone biology: Pathologic, molecular, and clinical correlates [J].
Cohen, M. Michael, Jr. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2006, 140A (23) :2646-2706